Security
Dogwood Therapeutics, Inc. Common Stock · DWTX
DWTXNASDAQCommon stockCurrentCIK 1818844Updated Nov 10, 2026
Name history
Virios Therapeutics, Inc. · through Oct 15, 2024Virios Therapeutics, LLC · through Dec 16, 2020
DWTX price & chart
Loading TradingView…
NASDAQ:DWTX on TradingView ↗About the company
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. Dogwood’s research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP.
In the news
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 ↗
Recent filings
EFFECT filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-3 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
Show 5 more recent filings
10-Q filing
SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding Dogwood Therapeutics, Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 91,992,613Source | 2,283,249Source | 80,495,480Source | 96,692,527Source | 3,635,889Source | 95,207,871Source | 96,984,688Source | 3,224,611Source | 90,171,237Source | 94,308,246Source | 4,165,442Source | 8,369,756Source |
| Property, Plant and Equipment, NetUSD | 15,293Source | — | 12,301Source | 16,179Source | — | 12,541Source | 15,899Source | — | 12,754Source | 16,811Source | — | — |
| GoodwillUSD | 12,209,591Source | — | 11,961,275Source | 12,458,383Source | — | 12,193,825Source | 11,823,159Source | — | 12,401,118Source | 11,812,476Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 67,919,601Source | — | 57,347,369Source | 69,303,582Source | — | 67,831,894Source | 65,769,949Source | — | 68,985,026Source | 65,710,527Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,126,710Source | 2,039,819Source | 9,610,033Source | 13,402,809Source | 3,020,183Source | 13,227,839Source | 17,539,004Source | 2,379,532Source | 6,524,744Source | 14,847,949Source | 3,316,946Source | 7,030,992Source |
| Assets, CurrentUSD | 11,655,377Source | 2,283,249Source | 11,025,905Source | 14,704,294Source | 3,635,889Source | 15,004,138Source | 19,163,772Source | 3,224,611Source | 8,431,206Source | 16,544,462Source | 4,165,442Source | 8,369,756Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,528,667Source | 243,430Source | 1,415,872Source | 1,301,485Source | 615,706Source | 1,776,299Source | 1,624,768Source | 845,079Source | 1,906,462Source | 1,696,513Source | 848,496Source | 1,338,764Source |
| Operating Lease, Right-of-Use AssetUSD | 174,008Source | — | 130,268Source | 190,964Source | — | 146,754Source | 193,759Source | — | 163,140Source | 205,837Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 14,607,504Source | 1,333,818Source | 12,129,372Source | 14,151,904Source | 500,076Source | 14,584,519Source | 14,235,733Source | 570,083Source | 15,274,370Source | 30,027,223Source | 358,548Source | 1,043,262Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 229Source | 111Source | 3,363Source | 191Source | 2,776Source | 3,340Source | 191Source | 1,926Source | 2,974Source | 133Source | 1,926Source | 1,833Source |
| Additional Paid in CapitalUSD | 73,158,686Source | 67,339,522Source | 196,246,223Source | 71,001,615Source | 67,242,537Source | 195,703,020Source | 70,937,136Source | 65,712,269Source | 183,856,376Source | 67,856,589Source | 65,573,300Source | 63,497,868Source |
| Retained Earnings (Accumulated Deficit)USD | -104,295,867Source | -66,091,074Source | -124,592,539Source | -88,551,251Source | -63,810,390Source | -113,062,930Source | -84,743,898Source | -62,760,557Source | -108,076,316Source | -73,818,946Source | -61,469,222Source | -56,173,207Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,636,135Source | — | -2,991,811Source | -267,289Source | — | -1,720,950Source | -3,801,831Source | — | -587,039Source | -3,862,987Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 7,258,152Source | 949,431Source | 68,366,108Source | 6,878,599Source | 3,135,813Source | 80,623,352Source | 7,086,931Source | 2,654,528Source | 74,896,867Source | -10,124,339Source | 3,806,894Source | 7,326,494Source |
| Liabilities and EquityUSD | 91,992,613Source | 2,283,249Source | 80,495,480Source | 96,692,527Source | 3,635,889Source | 95,207,871Source | 96,984,688Source | 3,224,611Source | 90,171,237Source | 94,308,246Source | 4,165,442Source | 8,369,756Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,596,809Source | 1,333,818Source | 2,831,295Source | 1,885,188Source | 500,076Source | 2,560,024Source | 2,579,825Source | 570,083Source | 3,059,203Source | 3,176,336Source | 358,548Source | 1,043,262Source |
| Operating Lease, Liability, CurrentUSD | 54,566Source | — | 57,645Source | 54,496Source | — | 57,314Source | 50,719Source | — | 56,841Source | 49,696Source | — | — |
| Accounts Payable, CurrentUSD | 584,602Source | 454,962Source | 411,516Source | 498,118Source | 217,762Source | 144,400Source | 1,153,642Source | 196,759Source | 760,945Source | 1,231,805Source | 111,913Source | 573,164Source |
| Operating Lease, Liability, NoncurrentUSD | 120,212Source | — | 69,563Source | 132,494Source | — | 87,616Source | 140,525Source | — | 105,763Source | 154,885Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | 11,890,483Source | — | 9,200,344Source | 12,134,222Source | — | 11,908,161Source | 11,515,383Source | — | 12,109,404Source | 11,314,925Source | 215,622Source | 340,865Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | 15,381,077Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,957,641Source | 878,856Source | 2,352,744Source | 1,332,574Source | 282,314Source | 2,348,737Source | 1,375,464Source | 373,324Source | 2,241,417Source | 1,894,835Source | 246,635Source | 470,098Source |
| Dividends Payable, Current | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -4,986,614Source | -10,924,952Source | -34,257,370Source | -12,349,724Source | -5,296,015Source | -12,247,834Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 449,419Source | 84,474Source | 355,642Source | 476,021Source | 619,972Source | 582,659Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -589,511Source | -131,477Source | -532,607Source | 219,888Source | -461,251Source | 219,301Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | -1,436Source | 0Source | -2,480,694Source | 149Source | 1,193Source | 190,542Source | 221,096Source | -503Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,587,187Source | -4,682,554Source | -15,618,651Source | -8,790,805Source | -4,870,489Source | -11,467,797Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 3,761,936Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 11,291,325Source | 7,372,378Source | 7,284,806Source | 16,704,464Source | 1,156,443Source | 4,490,605Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 10,126,710Source | 2,039,819Source | 9,610,033Source | 13,402,809Source | 13,227,839Source | 17,539,004Source | 6,524,744Source | 14,847,949Source | 3,316,946Source | 7,030,992Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | 52,373Source | 52,373Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 52,373Source | — | 58,432Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | 17,022Source | 2,063Source | 12,177Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -17,509Source | — | -30,569Source | 4,532Source | -5,860Source | -23,274Source | -27,916Source | -30,787Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -5,860Source | -6,886Source | -27,916Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -2,731Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | -6,134,120Source | -6,134,120Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,287,783Source | 1,766,010Source | 1,626,109Source | 1,353,172Source | 2,406,587Source | 1,992,928Source | 6,102,374Source | 8,696,335Source | 3,718,841Source | 4,245,681Source |
| GoodwillUSD | — | — | 12,209,591Source | — | 11,961,275Source | 12,458,383Source | 12,193,825Source | 11,823,159Source | 12,401,118Source | 11,812,476Source | — | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | 9,190,897Source | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 221,096Source | -503Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,744,616Source | -2,280,684Source | -11,529,609Source | -3,807,353Source | -4,986,614Source | -10,924,952Source | -34,257,370Source | -12,349,724Source | -5,296,015Source | -12,247,834Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -15,744,616Source | -2,280,684Source | -11,529,609Source | -3,807,353Source | -4,986,614Source | -12,181,614Source | -35,514,032Source | -12,863,829Source | — | — |
| Noncash Merger Related CostsUSD | — | — | — | — | — | — | — | — | — | 3,563,273Source | — | — |
| Operating ExpensesUSD | — | — | 15,809,125Source | 2,301,172Source | 14,063,525Source | 3,923,115Source | 5,076,366Source | 4,429,926Source | 27,968,445Source | 12,227,248Source | 5,446,919Source | 12,315,309Source |
| Other Nonoperating Income (Expense)USD | — | — | 63,073Source | 20,488Source | 53,222Source | 115,911Source | 90,945Source | -6,304,484Source | -6,067,829Source | -122,979Source | 150,904Source | 67,475Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 1,156,443Source | — |
| Dividends Payable, Current | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -15,809,125Source | -2,301,172Source | -14,063,525Source | -3,923,115Source | -5,076,366Source | -4,429,926Source | -27,968,445Source | -12,227,248Source | -5,446,919Source | -12,315,309Source |
| Other Nonoperating Income (Expense)USD | — | — | 63,073Source | 20,488Source | 53,222Source | 115,911Source | 90,945Source | -6,304,484Source | -6,067,829Source | -122,979Source | 150,904Source | 67,475Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -15,746,052Source | -2,280,684Source | -14,010,303Source | -3,807,204Source | -4,985,421Source | -10,734,410Source | -34,036,274Source | -12,350,227Source | -5,296,015Source | -12,247,834Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 221,096Source | -503Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,744,616Source | -2,280,684Source | -11,529,609Source | -3,807,353Source | -4,986,614Source | -10,924,952Source | -34,257,370Source | -12,349,724Source | -5,296,015Source | -12,247,834Source |
| Earnings Per Share, BasicUSD per share | — | — | -8.2Source | -2.05Source | -0.34Source | -1.99Source | -0.15Source | -8.45Source | -7.13Source | -12.52Source | -0.28Source | -1.11Source |
| Earnings Per Share, DilutedUSD per share | — | — | -8.2Source | -2.05Source | -0.34Source | -1.99Source | -0.15Source | -8.45Source | -7.13Source | -12.52Source | -0.28Source | -1.11Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,919,433Source | 1,110,317Source | 34,129,553Source | 1,911,128Source | 33,544,748Source | 1,441,535Source | 4,977,446Source | 1,027,788Source | 18,776,790Source | 11,070,116Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,919,433Source | 1,110,317Source | 34,129,553Source | 1,911,128Source | 33,544,748Source | 1,441,535Source | 4,977,446Source | 1,027,788Source | 18,776,790Source | 11,070,116Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -17,509Source | — | -30,569Source | 4,532Source | -5,860Source | -23,274Source | -27,916Source | -30,787Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,287,783Source | 1,766,010Source | 1,626,109Source | 1,353,172Source | 2,406,587Source | 1,992,928Source | 6,102,374Source | 8,696,335Source | 3,718,841Source | 4,245,681Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 150,904Source | 67,475Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 80,582Source | 20,488Source | 66,349Source | 111,379Source | 77,350Source | -147,090Source | 96,938Source | -92,192Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -15,744,616Source | -2,280,684Source | -11,529,609Source | -3,807,353Source | -4,986,614Source | -12,181,614Source | -35,514,032Source | -12,863,829Source | — | — |
| Operating ExpensesUSD | — | — | 15,809,125Source | 2,301,172Source | 14,063,525Source | 3,923,115Source | 5,076,366Source | 4,429,926Source | 27,968,445Source | 12,227,248Source | 5,446,919Source | 12,315,309Source |
| Research and Development ExpenseUSD | — | — | 14,521,342Source | 535,162Source | 3,246,519Source | 2,569,943Source | 2,669,779Source | 2,436,998Source | 21,866,071Source | 3,530,913Source | 1,728,078Source | 8,069,628Source |
| Business Combination, Acquisition Related Costs | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-299727
Registration 333-292750
Filing attachments
dwtx-ex99d1.htm · 8-K · 2026-11-05
Exhibit 99.1 Dogwood Therapeutics Announces Third Quarter 2026 Financial Results - Completed the Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing Halneuron® reduction in pain over three months of treatment with Halneuron® - - Closed $5M Private Placement with Sealbond Limited, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc., to Advanc…
Read attachment ↗dwtx-ex99d1.htm · 8-K · 2026-10-19
Exhibit 99.1 Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities - ATLANTA, Ga., October 19, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non…
Read attachment ↗dwtx-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 dwtx-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled - - Commencement of Phase 2b Long-Term Extension Study to assess Halneuron® reduction in pain over three months of treatment - - Appointment of Iain Dukes, D.Phil., Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - - A…
Read attachment ↗dwtx-20260514xex99d1.htm · 8-K · 2026-05-14
EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy - - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Do…
Read attachment ↗dwtx-20260326xex99d1.htm · 8-K · 2026-03-26
EX-99.1 2 dwtx-20260326xex99d1.htm EX-99.1 CEO Letter to Dogwood Therapeutics Shareholders: First Quarter 2026 Progress Report ALPHARETTA, Ga., March 26, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a development-stage biotechnology company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today issued a corporate update in the following Letter to Shareholders from CEO Greg Duncan. Dear Shareholders, Dogwood Therapeutics is a de…
Read attachment ↗dwtx-20260318xex99d1.htm · 8-K · 2026-03-18
EX-99.1 2 dwtx-20260318xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results ATLANTA, Ga., March 18, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitmen…
Read attachment ↗